

# Hyun Cheol Chung

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2836048/hyun-cheol-chung-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

354  
papers

15,194  
citations

47  
h-index

115  
g-index

368  
ext. papers

19,874  
ext. citations

5.2  
avg, IF

6.19  
L-index

#	Paper	IF	Citations
354	Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.. <i>Lancet Oncology, The, 2022,</i>	21.7	25
353	Tropomyosin-Related Kinase Fusions in Gastrointestinal Stromal Tumors. <i>Cancers, 2022, 14, 2659</i>	6.6	2
352	The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer.. <i>Nature, 2021, 600, 727-730</i>	50.4	36
351	409 Trial in progress: a phase 2 study to assess the safety, efficacy of FLX475 combined with pembrolizumab in patients with advanced or metastatic gastric cancer <b>2021, 9, A440-A440</b>		
350	Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. <i>Neuro-Oncology, 2021,</i>	1	4
349	CTNI-58. EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT AND PEDIATRIC PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION-POSITIVE PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS. <i>Neuro-Oncology, 2021, 23, vi73-vi74</i>	1	0
348	Inhibition of the bromodomain and extra-terminal family of epigenetic regulators as a promising therapeutic approach for gastric cancer. <i>Cellular Oncology (Dordrecht), 2021, 44, 1387-1403</i>	7.2	0
347	Evorpcept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. <i>Lancet Oncology, The, 2021, 22, 1740-1751</i>	21.7	2
346	Prognostic significance of T-cell-inflamed gene expression profile and PD-L1 expression in patients with esophageal cancer. <i>Cancer Medicine, 2021, 10, 8365-8376</i>	4.8	2
345	Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations. <i>Investigational New Drugs, 2021, 39, 1366-1374</i>	4.3	2
344	Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab. <i>Gastric Cancer, 2021, 24, 946-958</i>	7.6	13
343	Guidelines for Cancer Care during the COVID-19 Pandemic in South Korea. <i>Cancer Research and Treatment, 2021, 53, 323-329</i>	5.2	6
342	Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia. <i>Targeted Oncology, 2021, 16, 447-459</i>	5	8
341	Detection of asymptomatic recurrence improves survival of gastric cancer patients. <i>Cancer Medicine, 2021, 10, 3249-3260</i>	4.8	0
340	Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology, 2021, 74, 350-359</i>	13.4	51
339	Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population. <i>Gut, 2021, 70, 829-837</i>	19.2	27
338	First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811. <i>Future Oncology, 2021, 17, 491-501</i>	3.6	43

337	p16 methylation is a potential predictive marker for abemaciclib sensitivity in gastric cancer. <i>Biochemical Pharmacology</i> , <b>2021</b> , 183, 114320	6	2
336	Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 1267-1277	12.9	10
335	MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma. <i>Future Oncology</i> , <b>2021</b> , 17, 1155-1164	3.6	22
334	Comparative efficacy and tolerability of third-line treatments for advanced gastric cancer: A systematic review with Bayesian network meta-analysis. <i>European Journal of Cancer</i> , <b>2021</b> , 144, 49-60	7.5	7
333	Margetuximab (M) combined with anti-PD-1 (retifanlimab) or anti-PD-1/LAG-3 (tebotelimab) +/- chemotherapy (CTX) in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction (GEJ) or gastric cancer (GC).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS264-TPS264	2.2	3
332	LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumorsResults from the gastric cancer cohort.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 230-230	2.2	3
331	Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score $\geq 10$ . <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 1923-1931	12.9	23
330	Abstract PS12-07: Lenvatinib plus pembrolizumab for previously treated, advanced triple-negative breast cancer: Early results from the multicohort phase 2 LEAP-005 study <b>2021</b> ,		3
329	Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses. <i>Hepatology</i> , <b>2021</b> , 74, 1914-1931	11.2	5
328	Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061. <i>Gastric Cancer</i> , <b>2021</b> , 24, 1330-1340	7.6	1
327	Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study. <i>Gastric Cancer</i> , <b>2021</b> , 1	7.6	3
326	Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed therapies. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS475-TPS475	4.4	2
325	Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase II LEAP-005 study.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 321-321	2.2	8
324	A multi-institutional phase Ib/II trial of first-line triplet regimen (Pembrolizumab, Trastuzumab, Chemotherapy) for HER2-positive advanced gastric and gastroesophageal junction cancer (PANTHERA Trial): Molecular profiling and clinical update.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 218-218	2.2	9
323	LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumorsResults from the colorectal cancer cohort.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 94-94	2.2	10
322	MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinomaTrial in Progress.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS252-TPS252	2.2	4
321	Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients. <i>Cancer</i> , <b>2021</b> ,	6.4	2
320	Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. <i>International Journal of Cancer</i> , <b>2020</b> , 147, 2190-2198	7.5	107

319	Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 846-854	12.9	43
318	A phase I dose escalation study evaluating the safety and tolerability of a novel anti-HER2 antibody-drug conjugate (PF-06804103) in patients with HER2-positive solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 1039-1039	2.2	13
317	A phase I study of ALX148, a CD47 blocker, in combination with standard anticancer antibodies and chemotherapy regimens in patients with advanced malignancy.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3056-3056	2.2	7
316	Targeting HER2 in combination with anti-PD-1 and chemotherapy confers a significant tumor shrinkage of gastric cancer: A multi-institutional phase Ib/II trial of first-line triplet regimen (pembrolizumab, trastuzumab, chemotherapy) for HER2-positive advanced gastric cancer (AGC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3001-3001	2.2	13
315	Pembrolizumab versus paclitaxel for previously treated patients with PD-L1 $\beta$ positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4503-4503	2.2	19
314	The association of molecular biomarkers with efficacy of pembrolizumab versus paclitaxel in patients with gastric cancer (GC) from KEYNOTE-061.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4512-4512	2.2	16
313	Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized, phase II, multicenter, open-label study (DESTINY-Gastric01).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4513-4513	2.2	4
312	Pembrolizumab (pembro) versus standard of care chemotherapy (chemo) in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4523-4523	2.2	5
311	First-in-human phase I study of BVAC-B cell therapy in HER2-positive advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4534-4534	2.2	4
310	The association of tissue tumor mutational burden (tTMB) using the Foundation Medicine genomic platform with efficacy of pembrolizumab versus paclitaxel in patients (pts) with gastric cancer (GC) from KEYNOTE-061.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4537-4537	2.2	22
309	Safety and preliminary antitumor activity of the transforming growth factor beta (TGF- $\beta$ )receptor I kinase inhibitor, vactosertib, in combination with paclitaxel in patients with metastatic gastric adenocarcinoma.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e16505-e16505	2.2	2
308	Pembrolizumab vs paclitaxel as second-line treatment for Asian patients with PD-L1 $\beta$ positive advanced gastric or gastroesophageal cancer (GC) in the phase III KEYNOTE-063 trial.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e16586-e16586	2.2	2
307	ZW25, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, TPS3145-TPS3145	2.2	3
306	A phase III study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Three-year update data.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 383-383	2.2	7
305	Efficacy of pembrolizumab (pembro) monotherapy versus chemotherapy for PD-L1 $\beta$ positive (CPS $\geq$ 10) advanced G/GEJ cancer in the phase II KEYNOTE-059 (cohort 1) and phase III KEYNOTE-061 and KEYNOTE-062 studies.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 427-427	2.2	10
304	KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJc): A double-blind, randomized, placebo-controlled phase III study.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, TPS463-TPS463	2.2	3
303	Margetuximab (M) combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013) +/- chemotherapy (CTX) in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction (GEJ) or gastric cancer (GC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, TPS468-TPS468	2.2	2
302	Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + BL-8040 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 712-712	2.2	0

301	Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + PEGPH20 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4540-4540	2.2	0
300	Transcriptome analysis of iBET-151, a BET inhibitor alone and in combination with paclitaxel in gastric cancer cells. <i>Genomics and Informatics</i> , <b>2020</b> , 18, e37	1.9	1
299	Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 1-10	2.2	786
298	A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. <i>Gastric Cancer</i> , <b>2020</b> , 23, 510-519	7.6	72
297	Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, 618-627	8.9	116
296	Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer. <i>Molecular Therapy - Oncolytics</i> , <b>2020</b> , 18, 587-601	6.4	14
295	Gene Expression Profiling Identifies Akt as a Target for Radiosensitization in Gastric Cancer Cells. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 562284	5.3	
294	S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , <b>2020</b> , 21, 1045-1056	21.7	16
293	Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2020</b> , 6, 1571-1580	13.4	196
292	Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. <i>Lancet Oncology</i> , <b>2020</b> , 21, 1353-1365	21.7	500
291	Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer. <i>Gastric Cancer</i> , <b>2020</b> , 23, 143-153	7.6	26
290	Changes in taste and food preferences in breast cancer patients receiving chemotherapy: a pilot study. <i>Supportive Care in Cancer</i> , <b>2020</b> , 28, 1265-1275	3.9	3
289	Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 3202-3210	12.9	10
288	Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer <b>2019</b> , 7, 268		14
287	Inhibiting casein kinase 2 overcomes paclitaxel resistance in gastric cancer. <i>Gastric Cancer</i> , <b>2019</b> , 22, 1153-1163	14	
286	S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial. <i>Cancer Research and Treatment</i> , <b>2019</b> , 51, 1-11	5.2	13
285	Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer. <i>European Journal of Cancer</i> , <b>2019</b> , 112, 20-28	7.5	0
284	Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. <i>Gastric Cancer</i> , <b>2019</b> , 22, 828-837	7.6	112

283	Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1470-1478	2.2	364
282	Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial <b>2019</b> , 7, 30		43
281	Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial. <i>JAMA Network Open</i> , <b>2019</b> , 2, e198243	10.4	14
280	Phase II trial of preoperative sequential chemotherapy followed by chemoradiotherapy for high-risk gastric cancer. <i>Radiotherapy and Oncology</i> , <b>2019</b> , 140, 143-149	5.3	3
279	A phase I study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2514-2514	2.2	13
278	Efficacy and safety of pembrolizumab (pembro) alone or in combination with chemotherapy (chemo) in patients (pts) with advanced gastric or gastroesophageal (G/GEJ) cancer: Long-term follow up from KEYNOTE-059.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4009-4009	2.2	10
277	Prospective validation of a serum miRNA panel for early detection of gastric cancer.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4065-4065	2.2	1
276	Ramucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): Outcomes from two randomized phase 3 studies (REACH, REACH2).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4073-4073	2.2	6
275	Pembrolizumab (pembro) for advanced biliary adenocarcinoma: Results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4079-4079	2.2	61
274	KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJC): A double-blind, randomized, placebo-controlled phase 3 study.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, TPS4146-TPS4146	2.2	13
273	Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, LBA4007-LBA4007	2.2	102
272	Evaluation of efficacy of nivolumab by baseline factors from ATTRACTION-2.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 8-8	2.2	3
271	Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients. <i>Cancer Research and Treatment</i> , <b>2019</b> , 51, 211-222	5.2	5
270	Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial. <i>Cancer Research and Treatment</i> , <b>2019</b> , 51, 819-831	5.2	8
269	Behaviors and Attitudes toward the Use of Complementary and Alternative Medicine among Korean Cancer Patients. <i>Cancer Research and Treatment</i> , <b>2019</b> , 51, 851-860	5.2	8
268	T-cell-inflamed gene expression profile (GEP) and PD-L1 expression in patients (pts) with esophageal cancer (EC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 26-26	2.2	3
267	Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma. <i>Cancer Research and Treatment</i> , <b>2019</b> , 51, 1578-1588	5.2	1
266	Mesothelin Expression Is a Predictive Factor for Peritoneal Recurrence in Curatively Resected Stage III Gastric Cancer. <i>Oncologist</i> , <b>2019</b> , 24, e1108-e1114	5.7	9

265	Role of probe-based confocal laser endomicroscopy-targeted biopsy in the molecular and histopathological study of gastric cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2019</b> , 34, 84-91	4	13
264	Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma. <i>Oncology</i> , <b>2019</b> , 96, 59-69	3.6	9
263	A Multicenter Phase II Study of AMG 337 in Patients with -Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other -Amplified Solid Tumors. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 2414-2423	12.9	37
262	Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012. <i>Cancer Science</i> , <b>2018</b> , 109, 771-776	6.9	29
261	Identification of Natural Products as Novel PI3K Inhibitors Through Pharmacophore-based Virtual Screening. <i>Bulletin of the Korean Chemical Society</i> , <b>2018</b> , 39, 294-299	1.2	1
260	Forty-nine gastric cancer cell lines with integrative genomic profiling for development of c-MET inhibitor. <i>International Journal of Cancer</i> , <b>2018</b> , 143, 151-159	7.5	16
259	Subgroup analysis of East Asian patients in REGARD: A phase III trial of ramucirumab and best supportive care for advanced gastric cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2018</b> , 14, 204-209	1.9	5
258	The prognostic value of volume-based parameters using F-FDG PET/CT in gastric cancer according to HER2 status. <i>Gastric Cancer</i> , <b>2018</b> , 21, 213-224	7.6	14
257	Marked Loss of Muscle, Visceral Fat, or Subcutaneous Fat After Gastrectomy Predicts Poor Survival in Advanced Gastric Cancer: Single-Center Study from the CLASSIC Trial. <i>Annals of Surgical Oncology</i> , <b>2018</b> , 25, 3222-3230	3.1	40
256	Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept "3G" Trial. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 5272-5281	12.9	13
255	Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by H3K27me3 in sarcoma. <i>BMC Cancer</i> , <b>2018</b> , 18, 158	4.8	12
254	Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. <i>Lancet, The</i> , <b>2018</b> , 392, 123-133	40	624
253	Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study. <i>British Journal of Cancer</i> , <b>2018</b> , 119, 19-26	8.7	19
252	Safety and efficacy of durvalumab in combination with tremelimumab, durvalumab monotherapy, and tremelimumab monotherapy in patients with advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 4031-4031	2.2	9
251	Randomized, double-blind, phase 2 study of S-1 plus oxaliplatin (SOX) with or without ramucirumab (RAM) as first-line therapy followed by paclitaxel plus RAM as second-line therapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma (AGC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 4036-4036	2.2	4
250	Pembrolizumab (pembro) vs paclitaxel (PTX) for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Phase 3 KEYNOTE-061 trial.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 4062-4062	2.2	7
249	Pembrolizumab treatment of advanced cervical cancer: Updated results from the phase 2 KEYNOTE-158 study.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 5522-5522	2.2	44
248	Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 8506-8506	2.2	100

247	MORPHEUS: A phase Ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT) combinations in patients (pts) with gastric or pancreatic cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS4134-TPS4134	2.2	4
246	Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 90-90	2.2	1
245	Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials. <i>Journal of Global Oncology</i> , <b>2018</b> , 4, 1-12	2.6	6
244	Multidisciplinary treatment for patients with stage IV gastric cancer: the role of conversion surgery following chemotherapy. <i>BMC Cancer</i> , <b>2018</b> , 18, 1116	4.8	31
243	Casein Kinase 2 Inhibitor, CX-4945, as a Potential Targeted Anticancer Agent in Gastric Cancer. <i>Anticancer Research</i> , <b>2018</b> , 38, 6171-6180	2.3	7
242	Regulation of proliferation and invasion by the IGF signalling pathway in Epstein-Barr virus-positive gastric cancer. <i>Journal of Cellular and Molecular Medicine</i> , <b>2018</b> , 22, 5899-5908	5.6	3
241	MET in gastric cancer with liver metastasis: The relationship between MET amplification and Met overexpression in primary stomach tumors and liver metastasis. <i>Journal of Surgical Oncology</i> , <b>2018</b> , 117, 1679-1686	2.8	11
240	A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy. <i>AAPS Journal</i> , <b>2018</b> , 20, 72	3.7	
239	Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. <i>British Journal of Cancer</i> , <b>2018</b> , 119, 153-159	8.7	209
238	Differential Prognostic Implications of Gastric Signet Ring Cell Carcinoma: Stage Adjusted Analysis From a Single High-volume Center in Asia. <i>Annals of Surgery</i> , <b>2017</b> , 265, 946-953	7.8	84
237	ABCB1 2677G>T/A variant enhances chemosensitivity to anti-cancer agents acting on microtubule dynamics through LAMP1 inhibition. <i>Biochemical Pharmacology</i> , <b>2017</b> , 123, 73-84	6	2
236	Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2017</b> , 163, 255-262	4.4	3
235	A phase 1, open label, dose escalation study to investigate the safety, tolerability, and pharmacokinetics of MG1102 (apolipoprotein(a) Kringle V) in patients with solid tumors. <i>Investigational New Drugs</i> , <b>2017</b> , 35, 773-781	4.3	4
234	Modulation of HAT activity by the BRCA2 N372H variation is a novel mechanism of paclitaxel resistance in breast cancer cell lines. <i>Biochemical Pharmacology</i> , <b>2017</b> , 138, 163-173	6	8
233	Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study. <i>European Journal of Cancer</i> , <b>2017</b> , 81, 17-25	7.5	45
232	Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 640-653	21.7	254
231	A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2017</b> , 80, 1197-1207	3.5	19
230	Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , <b>2017</b> , 390, 2461-2471	40	1123



229	Feasibility of quantifying methylation in stool DNA for early detection of colorectal cancer. <i>Clinical Epigenetics</i> , <b>2017</b> , 9, 126	7.7	45
228	Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 61837-61845	6.1	10
227	Changes in telomerase activity due to alternative splicing of human telomerase reverse transcriptase in colorectal cancer. <i>Oncology Letters</i> , <b>2017</b> , 14, 2385-2392	2.6	5
226	A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 5981-5992	12.9	73
225	Prevalence and prognostic implications of psychological distress in patients with gastric cancer. <i>BMC Cancer</i> , <b>2017</b> , 17, 283	4.8	56
224	HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib. <i>Molecular Cancer Therapeutics</i> , <b>2017</b> , 16, 228-238	6.1	25
223	Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma: Analysis of REACH Trial Results by Child-Pugh Score. <i>JAMA Oncology</i> , <b>2017</b> , 3, 235-243	13.4	59
222	KEYNOTE-059 cohort 2: Safety and efficacy of pembrolizumab (pembro) plus 5-fluorouracil (5-FU) and cisplatin for first-line (1L) treatment of advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4012-4012	2.2	39
221	Pembrolizumab for previously treated advanced cervical squamous cell cancer: Preliminary results from the phase 2 KEYNOTE-158 study.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 5514-5514	2.2	49
220	Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): A double-blinded, randomized, phase III trial.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2-2	2.2	56
219	Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab. <i>Oncotarget</i> , <b>2017</b> , 8, 31169-31179	3.3	8
218	Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 38389-38398	3.3	7
217	PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 113494-113501	3.3	26
216	PD-L1 expression in patients with metastatic gastric cancer in South Korea.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1571-1571	2.2	1
215	A novel TP53-KPNA3 translocation defines a de novo treatment-resistant clone in osteosarcoma. <i>Journal of Physical Education and Sports Management</i> , <b>2016</b> , 2, a000992	2.8	11
214	High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2016</b> , 142, 2051-9	4.9	9
213	Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples. <i>Experimental and Molecular Pathology</i> , <b>2016</b> , 100, 287-434	4.4	24
212	Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma. <i>Annals of Nuclear Medicine</i> , <b>2016</b> , 30, 279-86	2.5	9

211	An update on the randomized phase III POST trial: S-1 based doublet as an adjuvant chemotherapy for curatively resected stage III gastric cancer.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4042-4042	2.2	1
210	Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 6010-6010	2.2	18
209	Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Pooled analyses after long-term follow-up in KEYNOTE-012.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 6012-6012	2.2	28
208	Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 167-167	2.2	26
207	Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus. <i>Oncotarget</i> , <b>2016</b> , 7, 10547-56	3.3	44
206	Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy. <i>Oncotarget</i> , <b>2016</b> , 7, 44608-44620	3.3	31
205	Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites. <i>Oncotarget</i> , <b>2016</b> , 7, 8055-66	3.3	28
204	PRL3-zumab, a first-in-class humanized antibody for cancer therapy. <i>JCI Insight</i> , <b>2016</b> , 1, e87607	9.9	32
203	Cumulative Metformin Use and Its Impact on Survival in Gastric Cancer Patients After Gastrectomy. <i>Annals of Surgery</i> , <b>2016</b> , 263, 96-102	7.8	43
202	Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. <i>BMC Cancer</i> , <b>2016</b> , 16, 434	4.8	93
201	Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 717-726	21.7	716
200	The Clinicopathologic Features and Prognostic Impact of ALK Positivity in Patients with Resected Gastric Cancer. <i>Annals of Surgical Oncology</i> , <b>2015</b> , 22, 3938-45	3.1	9
199	Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 859-70	21.7	542
198	Clinicopathological features and prognostic significance of HER2 expression in gastric cancer. <i>Oncology</i> , <b>2015</b> , 88, 147-56	3.6	14
197	PTEN deficiency as a predictive biomarker of resistance to HER2-targeted therapy in advanced gastric cancer. <i>Oncology</i> , <b>2015</b> , 88, 76-85	3.6	24
196	PINCH-2 presents functional copy number variation and suppresses migration of colon cancer cells by paracrine activity. <i>International Journal of Cancer</i> , <b>2015</b> , 136, 2273-83	7.5	9
195	Proper timing of adjuvant chemotherapy affects survival in patients with stage 2 and 3 gastric cancer. <i>Annals of Surgical Oncology</i> , <b>2015</b> , 22, 224-31	3.1	38
194	Do Recent Advances in Diagnostic and Therapeutic Procedures Negate the Benefit of Postmastectomy Radiotherapy in N1 Patients With a Low Risk of Locoregional Recurrence?. <i>Medicine (United States)</i> , <b>2015</b> , 94, e1259	1.8	14

193	Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. <i>Gut</i> , <b>2015</b> , 64, 1721-31	19.2	137
192	Incidence and Survival of Pediatric Soft Tissue Sarcomas: Comparison between Adults and Children. <i>Cancer Research and Treatment</i> , <b>2015</b> , 47, 9-17	5.2	7
191	Clinical pattern and implication of PD-L1 expression in soft-tissue sarcoma.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 10565-10565	2.2	5
190	Relationship between PD-L1 expression and clinical outcomes in patients (Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475) in KEYNOTE-012.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3-3	2.2	45
189	Dovitinib (TKI258), a multi-target angiokinase inhibitor, is effective regardless of KRAS or BRAF mutation status in colorectal cancer. <i>American Journal of Cancer Research</i> , <b>2015</b> , 5, 72-86	4.4	10
188	Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine. <i>Cancer Research and Treatment</i> , <b>2015</b> , 47, 781-9	5.2	7
187	Modeling post-progression survival in patients with HER2-positive metastatic gastric cancer.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e15020-e15020	2.2	
186	Next-generation sequencing to reveal somatic mutations that confer sensitivity to everolimus.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 11010-11010	2.2	
185	Prognostic impact of different FDG-PET uptake according to histology in advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4113-4113	2.2	
184	A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer. <i>Investigational New Drugs</i> , <b>2014</b> , 32, 561-8	4.3	2
183	Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , <b>2014</b> , 15, 1389-96	21.7	578
182	High KLF4 level in normal tissue predicts poor survival in colorectal cancer patients. <i>World Journal of Surgical Oncology</i> , <b>2014</b> , 12, 232	3.4	27
181	Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline: randomized phase II multicenter trial. <i>Investigational New Drugs</i> , <b>2014</b> , 32, 753-61	4.3	5
180	Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2039-49	2.2	407
179	Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2014</b> , 74, 799-808	3.5	6
178	Angiogenic factor thymidine phosphorylase associates with angiogenesis and lymphangiogenesis in the intestinal-type gastric cancer. <i>Pathology</i> , <b>2014</b> , 46, 316-24	1.6	15
177	The effect of disintegrin-metalloproteinase ADAM9 in gastric cancer progression. <i>Molecular Cancer Therapeutics</i> , <b>2014</b> , 13, 3074-85	6.1	30
176	Influence of the BDNF Val66Met polymorphism on coping response to stress in patients with advanced gastric cancer. <i>Journal of Psychosomatic Research</i> , <b>2014</b> , 77, 76-80	4.1	13

175	Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2014</b> , 140, 319-28	4.9	132
174	A phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2514-2514	2.2	17
173	MAPK-signaling inhibition as a genome-based precision medicine in refractory osteosarcoma.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e22164-e22164	2.2	
172	Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors. <i>Supportive Care in Cancer</i> , <b>2013</b> , 21, 1751-9	3.9	27
171	Application of the adjuvant! Online model to Korean breast cancer patients: an assessment of prognostic accuracy and development of an alternative prognostic tool. <i>Annals of Surgical Oncology</i> , <b>2013</b> , 20, 2615-24	3.1	17
170	Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer. <i>BMC Cancer</i> , <b>2013</b> , 13, 394	4.8	22
169	S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial. <i>BMC Cancer</i> , <b>2013</b> , 13, 583	4.8	6
168	Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent. <i>Investigational New Drugs</i> , <b>2013</b> , 31, 1-13	4.3	10
167	Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. <i>Nature Medicine</i> , <b>2013</b> , 19, 329-36	50.5	525
166	Genome-wide identification and validation of a novel methylation biomarker, SDC2, for blood-based detection of colorectal cancer. <i>Journal of Molecular Diagnostics</i> , <b>2013</b> , 15, 498-507	5.1	102
165	Estimating the adjuvant chemotherapy effect in elderly stage II and III colon cancer patients in an observational study. <i>Journal of Surgical Oncology</i> , <b>2013</b> , 107, 613-8	2.8	17
164	Therapeutic strategies for well-differentiated papillary mesothelioma of the peritoneum. <i>Japanese Journal of Clinical Oncology</i> , <b>2013</b> , 43, 996-1003	2.8	23
163	Mechanism of enhancement of radiation-induced cytotoxicity by sorafenib in colorectal cancer. <i>Journal of Radiation Research</i> , <b>2013</b> , 54, 52-60	2.4	9
162	Changing treatment patterns in elderly patients with resectable colon cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2013</b> , 9, 265-72	1.9	8
161	Telomerase- and angiogenesis-related gene responses to irradiation in human umbilical vein endothelial cells. <i>International Journal of Molecular Medicine</i> , <b>2013</b> , 31, 1202-8	4.4	7
160	A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 492-492	2.2	1
159	The effect of delay of adjuvant chemotherapy on survival in patients with resected stage II and III gastric cancer.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e15144-e15144	2.2	
158	Clinicopathologic features predicting HER2 overexpression in gastric cancer.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e15098-e15098	2.2	

157	A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancer. <i>Investigational New Drugs</i> , <b>2012</b> , 30, 357-63	4.3	5
156	A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy. <i>Investigational New Drugs</i> , <b>2012</b> , 30, 672-80	4.3	14
155	Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. <i>Lancet, The</i> , <b>2012</b> , 379, 315-21	4.0	1085
154	Body image, sexual function and depression in Korean patients with breast cancer: modification by 5-HTT polymorphism. <i>Supportive Care in Cancer</i> , <b>2012</b> , 20, 2177-82	3.9	12
153	FKBP5 polymorphisms as vulnerability to anxiety and depression in patients with advanced gastric cancer: a controlled and prospective study. <i>Psychoneuroendocrinology</i> , <b>2012</b> , 37, 1569-76	5	29
152	A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. <i>European Journal of Cancer</i> , <b>2012</b> , 48, 518-26	7.5	98
151	Identification of a radiosensitivity signature using integrative metaanalysis of published microarray data for NCI-60 cancer cells. <i>BMC Genomics</i> , <b>2012</b> , 13, 348	4.5	80
150	Application of the Western-based adjuvant online model to Korean colon cancer patients; a single institution experience. <i>BMC Cancer</i> , <b>2012</b> , 12, 471	4.8	1
149	AMPK $\alpha$ modulation in cancer progression: multilayer integrative analysis of the whole transcriptome in Asian gastric cancer. <i>Cancer Research</i> , <b>2012</b> , 72, 2512-21	10.1	82
148	A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDGF) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy. <i>Investigational New Drugs</i> , <b>2012</b> , 30, 1501-10	4.3	17
147	High levels of serum VEGF and TIMP-1 are correlated with colon cancer liver metastasis and intrahepatic recurrence after liver resection. <i>Oncology Letters</i> , <b>2012</b> , 4, 123-130	2.6	20
146	Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy. <i>PLoS ONE</i> , <b>2012</b> , 7, e45127	3.7	13
145	Methylation status of lamin A/C in gastric cancer cell lines. <i>Hepato-Gastroenterology</i> , <b>2012</b> , 59, 1313-8		3
144	Prognostic significance of intermediate mucinous carcinoma in patients with microsatellite stable stage II or III colon cancer. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3606-3606	2.2	
143	Comparison of S-1 and cisplatin combination versus S-1 adjuvant chemotherapy for advanced gastric cancer. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e14652-e14652	2.2	
142	Mucinous histology to predict disease-free survival in microsatellite stable stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e14084-e14084	2.2	
141	CD44-SLC1A2 gene fusions in gastric cancer. <i>Science Translational Medicine</i> , <b>2011</b> , 3, 77ra30	17.5	43
140	Inflammatory and tumor stimulating responses after laparoscopic sigmoidectomy. <i>Yonsei Medical Journal</i> , <b>2011</b> , 52, 635-42	3	1

139	Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer. <i>Anti-Cancer Drugs</i> , <b>2011</b> , 22, 801-10	2.4	13
138	Genome-wide molecular characterization of mucinous colorectal adenocarcinoma using cDNA microarray analysis. <i>Oncology Reports</i> , <b>2011</b> , 25, 717-27	3.5	11
137	Treatment of recurrent hepatocellular carcinoma after liver transplantation. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2011</b> , 7, 258-69	1.9	9
136	Prevalence and associated factors of psychological distress among Korean cancer patients. <i>General Hospital Psychiatry</i> , <b>2011</b> , 33, 246-52	5.6	28
135	Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells. <i>Breast Cancer Research and Treatment</i> , <b>2011</b> , 125, 55-63	4.4	45
134	Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2011</b> , 137, 1123-30	4.9	24
133	Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2011</b> , 68, 991-9	3.5	4
132	A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy. <i>Cancer</i> , <b>2011</b> , 117, 2050-7	6.4	38
131	A prognostic model to predict clinical outcome in gastric cancer patients with bone metastasis. <i>Oncology</i> , <b>2011</b> , 80, 142-50	3.6	32
130	Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles. <i>Oncology</i> , <b>2011</b> , 80, 395-405	3.6	45
129	Advanced detection of recent changing trends in gastric cancer survival: up-to-date comparison by period analysis. <i>Japanese Journal of Clinical Oncology</i> , <b>2011</b> , 41, 1344-50	2.8	13
128	A densely interconnected genome-wide network of microRNAs and oncogenic pathways revealed using gene expression signatures. <i>PLoS Genetics</i> , <b>2011</b> , 7, e1002415	6	26
127	Is pyridoxine helpful in preventing palmar-plantar erythrodysesthesia associated with capecitabine?. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2010</b> , 6, 141-3	1.9	3
126	Chemokine growth-regulated oncogene 1 as a putative biomarker for gastric cancer progression. <i>Cancer Science</i> , <b>2010</b> , 101, 2200-6	6.9	19
125	Efficacy and feasibility of radiofrequency ablation for liver metastases from gastric adenocarcinoma. <i>International Journal of Hyperthermia</i> , <b>2010</b> , 26, 305-15	3.7	40
124	A comparative study of protein expression in primary colorectal cancer and synchronous hepatic metastases: the significance of matrix metalloproteinase-1 expression as a predictor of liver metastasis. <i>Scandinavian Journal of Gastroenterology</i> , <b>2010</b> , 45, 217-25	2.4	15
123	Two dosages of oral fluoropyrimidine S-1 of 35 and 40 mg/m <sup>2</sup> bid: comparison of the pharmacokinetic profiles in Korean patients with advanced gastric cancer. <i>Japanese Journal of Clinical Oncology</i> , <b>2010</b> , 40, 29-35	2.8	2
122	Circulating endothelial progenitor cells (EPC) for tumor vasculogenesis in gastric cancer patients. <i>Cancer Letters</i> , <b>2010</b> , 288, 124-32	9.9	30

121	Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancer. <i>Radiotherapy and Oncology</i> , <b>2010</b> , 95, 303-7	5.3	21
120	A phase II study of a combined biweekly irinotecan and monthly cisplatin treatment for metastatic or recurrent gastric cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2010</b> , 33, 56-60	2.7	2
119	The clinical outcome of chemotherapy-induced amenorrhea in premenopausal young patients with breast cancer with long-term follow-up. <i>Annals of Surgical Oncology</i> , <b>2010</b> , 17, 3259-68	3.1	38
118	Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2010</b> , 66, 425-31	3.5	
117	Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2010</b> , 66, 797-805	3.5	20
116	The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2010</b> , 136, 517-26	4.9	24
115	Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2010</b> , 136, 1901-13	4.9	20
114	A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer. <i>Investigational New Drugs</i> , <b>2010</b> , 28, 650-8	4.3	15
113	Identification of novel gastric cancer-associated CNVs by integrated analysis of microarray. <i>Journal of Surgical Oncology</i> , <b>2010</b> , 102, 454-61	2.8	9
112	Clinicopathologic features of metachronous or synchronous gastric cancer patients with three or more primary sites. <i>Cancer Research and Treatment</i> , <b>2010</b> , 42, 217-24	5.2	20
111	Genetic and epigenetic marker-based DNA test of stool is a promising approach for colorectal cancer screening. <i>Yonsei Medical Journal</i> , <b>2009</b> , 50, 331-4	3	5
110	Benefits of recurrent colonic stent insertion in a patient with advanced gastric cancer with carcinomatosis causing colonic obstruction. <i>Yonsei Medical Journal</i> , <b>2009</b> , 50, 296-9	3	2
109	A phase II feasibility study of weekly paclitaxel in heavily pretreated advanced gastric cancer patients with poor performance status. <i>Oncology</i> , <b>2009</b> , 77, 349-57	3.6	5
108	Oncogenic pathway combinations predict clinical prognosis in gastric cancer. <i>PLoS Genetics</i> , <b>2009</b> , 5, e1000676	2.79	
107	A weighted sample size for microarray datasets that considers the variability of variance and multiplicity. <i>Journal of Bioscience and Bioengineering</i> , <b>2009</b> , 108, 252-8	3.3	6
106	The effect of spleen-preserving lymphadenectomy on surgical outcomes of locally advanced proximal gastric cancer. <i>Journal of Surgical Oncology</i> , <b>2009</b> , 99, 275-80	2.8	42
105	Increments of alpha-dystroglycan expression in liver metastasis correlate with poor survival in gastric cancer. <i>Journal of Surgical Oncology</i> , <b>2009</b> , 100, 459-65	2.8	7
104	Standardized genetic alteration score and predicted score for predicting recurrence status of gastric cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2009</b> , 135, 1501-12	4.9	2

103	Prediction of S-1-induced anemia. <i>Gastric Cancer</i> , <b>2009</b> , 12, 23-30	7.6	
102	Postoperative adjuvant chemotherapy of gastric cancer: scrutiny into the clinical evidence based on quality assessment of medical literature of randomized controlled trials. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2009</b> , 63, 919-27	3.5	5
101	Effect of being overweight on postoperative morbidity and long-term surgical outcomes in proximal gastric carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2009</b> , 24, 475-9	4	24
100	Prediction of recurrence of early gastric cancer after curative resection. <i>Annals of Surgical Oncology</i> , <b>2009</b> , 16, 1896-902	3.1	68
99	G-T haplotype (2677G>T/A and 3435C>T) of ABCB1 gene polymorphisms is associated with ethnic differences to paclitaxel sensitivity in cancer cells with different gene expression pattern. <i>Cancer Letters</i> , <b>2009</b> , 277, 155-63	9.9	12
98	Subtelomeric DNA methylation and telomere length in human cancer cells. <i>Cancer Letters</i> , <b>2009</b> , 281, 82-91	9.9	14
97	In vitro pharmacogenomic database and chemosensitivity predictive genes in gastric cancer. <i>Genomics</i> , <b>2009</b> , 93, 52-61	4.3	13
96	Identification of significant regional genetic variations using continuous CNV values in aCGH data. <i>Genomics</i> , <b>2009</b> , 94, 317-23	4.3	3
95	Expression of anaphase-promoting complex7 in fibroadenomas and phyllodes tumors of breast. <i>Human Pathology</i> , <b>2009</b> , 40, 98-107	3.7	9
94	Prediction of high-risk patients by genome-wide copy number alterations from remaining cancer after neoadjuvant chemotherapy and surgery. <i>International Journal of Oncology</i> , <b>2009</b> , 34, 837-46	1	2
93	Copy number changes can be a predictor for hemoglobin reduction after S-1 monotherapy in gastric cancer. <i>International Journal of Oncology</i> , <b>2009</b> , 34, 787-96	1	1
92	Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. <i>Cancer Research and Treatment</i> , <b>2009</b> , 41, 67-72	5.2	57
91	Prognosis of pN3 stage gastric cancer. <i>Cancer Research and Treatment</i> , <b>2009</b> , 41, 73-9	5.2	16
90	Docetaxel versus paclitaxel combined with 5-FU and leucovorin in advanced gastric cancer: combined analysis of two phase II trials. <i>Cancer Research and Treatment</i> , <b>2009</b> , 41, 196-204	5.2	21
89	Improving the prediction accuracy in classification using the combined data sets by ranks of gene expressions. <i>BMC Bioinformatics</i> , <b>2008</b> , 9, 283	3.6	14
88	Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: long-term results in 31 patients. <i>BMC Cancer</i> , <b>2008</b> , 8, 8	4.8	11
87	Variation of the 3Ntelomeric overhang lengths in human cells. <i>Cancer Letters</i> , <b>2008</b> , 264, 107-18	9.9	10
86	Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer. <i>Cancer Letters</i> , <b>2008</b> , 270, 269-76	9.9	5



85	Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer. <i>Radiotherapy and Oncology</i> , <b>2008</b> , 87, 361-6	5.3	8
84	Angiogenic factor thymidine phosphorylase increases cancer cell invasion activity in patients with gastric adenocarcinoma. <i>Molecular Cancer Research</i> , <b>2008</b> , 6, 1554-66	6.6	26
83	Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel beta-catenin/TCF target gene. <i>Cancer Research</i> , <b>2008</b> , 68, 4277-86	10.1	74
82	Cyclooxygenase-2 expression in pretreatment biopsy as a predictor of tumor responses after preoperative chemoradiation in rectal cancer. <i>Archives of Surgery</i> , <b>2008</b> , 143, 1091-7; discussion 1097		17
81	Novel biomarker candidates for gastric cancer. <i>Oncology Reports</i> , <b>2008</b> ,	3.5	2
80	The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2008</b> , 61, 75-81	3.5	9
79	Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2008</b> , 61, 157-65	3.5	11
78	A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2008</b> , 61, 315-21	3.5	15
77	Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2008</b> , 108, 241-50	4.4	425
76	Pemetrexed and cisplatin in patients with advanced gastric cancer: a Korean cancer study group multicenter phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2008</b> , 62, 263-70	3.5	10
75	Standardization of the Korean version of Mini-Mental Adjustment to Cancer (K-Mini-MAC) scale: factor structure, reliability and validity. <i>Psycho-Oncology</i> , <b>2008</b> , 17, 592-7	3.9	45
74	S-1 monotherapy as a neoadjuvant treatment for locally advanced gastric cancer. <i>Korean Journal of Internal Medicine</i> , <b>2008</b> , 23, 37-41	2.5	
73	Cetuximab rescue a patient with non-small cell lung cancer from rapid disease progression during chemotherapy. <i>Acta Oncologica</i> , <b>2007</b> , 46, 547-9	3.2	0
72	Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: a 15-year experience at a single institute. <i>Journal of Surgical Oncology</i> , <b>2007</b> , 95, 461-8	2.8	67
71	A comparative study of volumetric analysis, histopathologic downstaging, and tumor regression grade in evaluating tumor response in locally advanced rectal cancer following preoperative chemoradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2007</b> , 67, 204-10	4	54
70	Novel and simple transformation algorithm for combining microarray data sets. <i>BMC Bioinformatics</i> , <b>2007</b> , 8, 218	3.6	9
69	Genome-wide genetic aberrations of thymoma using cDNA microarray based comparative genomic hybridization. <i>BMC Genomics</i> , <b>2007</b> , 8, 305	4.5	23
68	Gastrointestinal stromal tumor of the rectum: an analysis of seven cases. <i>Surgery Today</i> , <b>2007</b> , 37, 455-9	3	24

67	Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute. <i>Annals of Surgical Oncology</i> , <b>2007</b> , 14, 2730-7	3.1	56
66	Different criteria for HER2 positivity by IHC can be applied in post-chemotherapy specimens in determining HER2 as a prognosticator in locally advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2007</b> , 104, 31-7	4.4	2
65	A phase II trial of weekly fractionated irinotecan and cisplatin for advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2007</b> , 59, 313-20	3.5	7
64	Multi-institutional phase II study of S-1 monotherapy in advanced gastric cancer with pharmacokinetic and pharmacogenomic evaluations. <i>Oncologist</i> , <b>2007</b> , 12, 543-54	5.7	31
63	An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients. <i>Oncologist</i> , <b>2007</b> , 12, 622-30	5.7	46
62	Bilateral breast cancer: differential diagnosis using histological and biological parameters. <i>Japanese Journal of Clinical Oncology</i> , <b>2007</b> , 37, 487-92	2.8	26
61	Identification of genes with correlated patterns of variations in DNA copy number and gene expression level in gastric cancer. <i>Genomics</i> , <b>2007</b> , 89, 451-9	4.3	51
60	Molecular basis of the differences between normal and tumor tissues of gastric cancer. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , <b>2007</b> , 1772, 1033-40	6.9	33
59	Anti-tumor activity of N-hydroxy-7-(2-naphthylthio) heptanamide, a novel histone deacetylase inhibitor. <i>Biochemical and Biophysical Research Communications</i> , <b>2007</b> , 356, 233-8	3.4	19
58	An attempt for combining microarray data sets by adjusting gene expressions. <i>Cancer Research and Treatment</i> , <b>2007</b> , 39, 74-81	5.2	4
57	A locally advanced breast cancer with difficult differential diagnosis of carcinosarcoma and atypical medullary carcinoma, which had poor response to adriamycin- and taxane-based neoadjuvant chemotherapy: a case report. <i>Cancer Research and Treatment</i> , <b>2007</b> , 39, 134-7	5.2	4
56	Integrated in silico and biological validation of the blocking effect of Cot-1 DNA on Microarray-CGH. <i>International Journal of Molecular Medicine</i> , <b>2007</b> , 19, 901-8	4.4	2
55	A phase II study of infusional 5-fluorouracil and low-dose leucovorin with docetaxel for advanced gastric cancer. <i>Oncology</i> , <b>2006</b> , 70, 63-70	3.6	15
54	Intermediate dose 5-fluorouracil-induced encephalopathy. <i>Japanese Journal of Clinical Oncology</i> , <b>2006</b> , 36, 55-9	2.8	42
53	Activation of hypoxia-inducible factor-1alpha is necessary for lysophosphatidic acid-induced vascular endothelial growth factor expression. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 6351-8	12.9	75
52	Statistical Issues in the Search for Biomarkers of Colorectal Cancer Using Microarray Experiments. <i>Wiley Series in Probability and Statistics</i> , <b>2006</b> , 333-343	1.3	1
51	Severe hypothyroidism induced by thyroid metastasis of colon adenocarcinoma: a case report and review of the literature. <i>Endocrine Journal</i> , <b>2006</b> , 53, 339-43	2.9	13
50	Systematic analysis of cDNA microarray-based CGH. <i>International Journal of Molecular Medicine</i> , <b>2006</b> , 17, 261	4.4	

49	Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines. <i>Pharmacogenetics and Genomics</i> , <b>2006</b> , 16, 429-38	1.9	45
48	Long-term survival after surgical resection for liver metastasis from gastric cancer: two case reports. <i>Cancer Research and Treatment</i> , <b>2006</b> , 38, 184-8	5.2	1
47	Quantitative detection of telomerase activity by real-time TRAP assay in the body fluids of cancer patients. <i>International Journal of Molecular Medicine</i> , <b>2005</b> , 16, 857	4.4	1
46	Attenuation of telomerase activity by hammerhead ribozyme targeting human telomerase RNA induces growth retardation and apoptosis in human breast tumor cells. <i>International Journal of Cancer</i> , <b>2005</b> , 114, 484-9	7.5	38
45	Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2005</b> , 90, 215-21	4.4	54
44	Cyclic induction of senescence with intermittent AZT treatment accelerates both apoptosis and telomere loss. <i>Breast Cancer Research and Treatment</i> , <b>2005</b> , 93, 227-36	4.4	30
43	A pilot study of trans-arterial injection of 166Holmium-Chitosan complex for treatment of small hepatocellular carcinoma. <i>Yonsei Medical Journal</i> , <b>2005</b> , 46, 799-805	3	8
42	Determination of genes related to gastrointestinal tract origin cancer cells using a cDNA microarray. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 79-86	12.9	23
41	The pattern of gene copy number changes in bilateral breast cancer surveyed by cDNA microarray-based comparative genomic hybridization. <i>International Journal of Molecular Medicine</i> , <b>2004</b> , 13, 17	4.4	
40	Tumor-specific gene therapy for uterine cervical cancer using MN/CA9-directed replication-competent adenovirus. <i>Cancer Gene Therapy</i> , <b>2004</b> , 11, 532-8	5.4	9
39	Coordination modes vs. antitumor activity: synthesis and antitumor activity of novel platinum(II) complexes of N-substituted amino dicarboxylic acids. <i>Journal of Inorganic Biochemistry</i> , <b>2004</b> , 98, 98-104	4.2	38
38	Lack of correlation between P-glycoprotein and chemotherapy resistance in nasal NK/T-cell lymphomas. <i>Leukemia and Lymphoma</i> , <b>2004</b> , 45, 1857-64	1.9	14
37	Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines. <i>Cancer Letters</i> , <b>2004</b> , 214, 215-24	9.9	59
36	Genome-scale analysis of resveratrol-induced gene expression profile in human ovarian cancer cells using a cDNA microarray <b>2003</b> , 22, 741		8
35	Biological phenotype determination with ex vivo model in gastric cancer for matrix-metalloproteinase inhibitor treatment. <i>International Journal of Molecular Medicine</i> , <b>2002</b> , 10, 251	4.4	0
34	Early postoperative intraperitoneal chemotherapy with mitomycin C, 5-fluorouracil and cisplatin for advanced gastric cancer. <i>Oncology</i> , <b>2001</b> , 60, 24-30	3.6	16
33	The significance of granzyme B expression in patients with angiocentric lymphoma of the head and neck. <i>Cancer</i> , <b>2001</b> , 91, 2343-2352	6.4	8
32	Correlation of tissue and blood plasminogen activation system in breast cancer. <i>Cancer Letters</i> , <b>2000</b> , 150, 137-45	9.9	20

31	Urinary 5-hydroxyindoleacetic acid (5-HIAA) excretion before and during cisplatin chemotherapy in patients with intrathoracic malignancy. <i>Tuberculosis and Respiratory Diseases</i> , <b>1999</b> , 46, 811		1
30	Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients. <i>Breast Cancer Research and Treatment</i> , <b>1998</b> , 49, 41-50	4.4	11
29	An unusual case of gastric carcinoma with synchronous non-Hodgkin's lymphoma. <i>Yonsei Medical Journal</i> , <b>1998</b> , 39, 463-7	3	1
28	Immunohistochemical Expression of c-erbB2, c-erbB3 and c-erbB4 Protein in Breast Cancer. <i>Journal of Korean Breast Cancer Society</i> , <b>1998</b> , 1, 215		1
27	Synchronous elevation of soluble intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) correlates with gastric cancer progression. <i>Yonsei Medical Journal</i> , <b>1998</b> , 39, 27-36	3	18
26	Relationship between p53 overexpression and gastric cancer progression. <i>Oncology</i> , <b>1997</b> , 54, 166-70	3.6	17
25	Comparison of biological phenotypes according to midkine expression in gastric cancer cells and their autocrine activities could be modulated by pentosan polysulfate. <i>Cancer Letters</i> , <b>1997</b> , 118, 37-46	9.9	14
24	Clinical and Mammographic Findings of Primary Lymphoma of the Breast. <i>Journal of the Korean Radiological Society</i> , <b>1997</b> , 37, 177		
23	Sequential production and activation of matrix-metalloproteinase-9 (MMP-9) with breast cancer progression. <i>Breast Cancer Research and Treatment</i> , <b>1997</b> , 43, 175-81	4.4	36
22	P-glycoprotein: the intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>1997</b> , 42, 65-72	4.4	38
21	Correlation between K-ras gene mutation and prognosis of patients with nonsmall cell lung carcinoma. <i>Cancer</i> , <b>1997</b> , 79, 462-7	6.4	40
20	High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma <b>1997</b> , 79, 878-883		43
19	Retrospective comparison of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (modified FAM) combination chemotherapy versus palliative therapy in treatment of advanced gastric cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>1997</b> , 20, 484-9	2.7	10
18	A comparative study of intravenous granisetron versus intravenous and oral ondansetron in the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>1997</b> , 20, 569-72	2.7	11
17	Role of Mammography in Evaluating Residual Cancer after Neo-adjuvant Chemotherapy of Locally Advanced Breast Carcinoma: Compared with Clinical Examination. <i>Journal of the Korean Radiological Society</i> , <b>1997</b> , 36, 1081		
16	High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma <b>1997</b> , 79, 878		2
15	P-glycoprotein as an intermediate end point of drug resistance to neoadjuvant chemotherapy in locally advanced gastric cancer. <i>Yonsei Medical Journal</i> , <b>1996</b> , 37, 397-404	3	5
14	Overexpression of c-ErbB-2 protein in gastric cancer by immunohistochemical stain. <i>Oncology</i> , <b>1996</b> , 53, 192-7	3.6	27

13	Sequential activation and production of matrix metalloproteinase-2 during breast cancer progression. <i>Clinical and Experimental Metastasis</i> , <b>1996</b> , 14, 512-9	4.7	39
12	Gastric cancer in young patients who underwent curative resection. Comparative study with older patients. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>1996</b> , 19, 45-8	2.7	28
11	Perioperative blood transfusions and prognosis in patients with curatively resected locally advanced gastric cancer. <i>Oncology</i> , <b>1995</b> , 52, 170-5	3.6	23
10	Point mutation at codon 12 of the c-Ha-ras gene in human gastric cancers. <i>Journal of Korean Medical Science</i> , <b>1992</b> , 7, 110-5	4.7	8
9	The value of immunohistochemical detection of P-glycoprotein in breast cancer before and after induction chemotherapy. <i>Yonsei Medical Journal</i> , <b>1992</b> , 33, 137-42	3	16
8	Should all the N3 lymph nodes group metastasis be regarded as distant metastasis (M1) in curatively resected gastric cancer?. <i>Yonsei Medical Journal</i> , <b>1992</b> , 33, 143-52	3	1
7	Coexisting mycosis fungoides and Hodgkin's disease as a composite lymphoma: a case report. <i>Yonsei Medical Journal</i> , <b>1991</b> , 32, 362-9	3	5
6	Expression of prognostic factors (EGFR, ER) by immunohistochemical staining method in male breast cancer. <i>Yonsei Medical Journal</i> , <b>1991</b> , 32, 126-30	3	6
5	Male breast cancer--a 20-year review of 16 cases at Yonsei University. <i>Yonsei Medical Journal</i> , <b>1990</b> , 31, 242-50	3	10
4	Locally advanced unresectable gastric cancer successfully resected after neoadjuvant chemotherapy with FADE regimen. <i>Yonsei Medical Journal</i> , <b>1990</b> , 31, 74-9	3	3
3	Comparison of adjuvant radiotherapy and chemoradiotherapy following surgery in stage IE and IIE primary gastrointestinal tract non-Hodgkin's lymphoma. <i>Yonsei Medical Journal</i> , <b>1990</b> , 31, 144-55	3	6
2	Pleural aspergillosis. <i>Yonsei Medical Journal</i> , <b>1988</b> , 29, 84-8	3	3
1	Pregnancy-associated osteoporosis. <i>Yonsei Medical Journal</i> , <b>1988</b> , 29, 286-94	3	14